Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

M. Klanova, MZ. Oestergaard, M. Trněný, W. Hiddemann, R. Marcus, LH. Sehn, U. Vitolo, A. Bazeos, V. Goede, H. Zeuner, A. Knapp, D. Sahin, N. Spielewoy, CR. Bolen, A. Cardona, C. Klein, JM. Venstrom, T. Nielsen, G. Fingerle-Rowson,

. 2019 ; 25 (15) : 4634-4643. [pub] 20190503

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025732

PURPOSE: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with worse outcome in patients receiving antibody-based therapy. PATIENTS AND METHODS: Baseline peripheral blood NKCC was assessed by flow cytometry (CD3-CD56+ and/or CD16+ cells) in 1,064 of 1,202 patients with follicular lymphoma treated with obinutuzumab or rituximab plus chemotherapy in the phase III GALLIUM trial (NCT01332968) and 1,287 of 1,418 patients with diffuse large B-cell lymphoma (DLBCL) treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP or R-CHOP) in the phase III GOYA trial (NCT01287741). The prognostic value of tumor NK-cell gene expression, as assessed by whole-transcriptome gene expression using TruSeq RNA sequencing, was also analyzed. The association of baseline variables, such as treatment arm, was evaluated using multivariate Cox regression models using a stepwise approach. RESULTS: In this exploratory analysis, low baseline peripheral blood NKCC was associated with shorter progression-free survival (PFS) in both follicular lymphoma [hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.02-2.14; P = 0.04] and DLBCL (HR, 1.36; 95% CI, 1.01-1.83; P = 0.04), and overall survival in follicular lymphoma (HR, 2.20; 95% CI, 1.26-3.86; P = 0.0058). Low tumor NK-cell gene expression was associated with shorter PFS in G-CHOP-treated patients with DLBCL (HR, 1.95; 95% CI, 1.22-3.15; P < 0.01). CONCLUSIONS: These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20-based immunochemotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025732
003      
CZ-PrNML
005      
20201222155404.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-18-3270 $2 doi
035    __
$a (PubMed)31053601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klanova, Magdalena $u Charles University General Hospital, Prague, Czech Republic. magda.klanova@lf1.cuni.cz mikkel.oestergaard@roche.com. Institute of Pathological Physiology, Charles University, Prague, Czech Republic. F. Hoffmann-La Roche Ltd, Basel, Switzerland.
245    10
$a Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy / $c M. Klanova, MZ. Oestergaard, M. Trněný, W. Hiddemann, R. Marcus, LH. Sehn, U. Vitolo, A. Bazeos, V. Goede, H. Zeuner, A. Knapp, D. Sahin, N. Spielewoy, CR. Bolen, A. Cardona, C. Klein, JM. Venstrom, T. Nielsen, G. Fingerle-Rowson,
520    9_
$a PURPOSE: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with worse outcome in patients receiving antibody-based therapy. PATIENTS AND METHODS: Baseline peripheral blood NKCC was assessed by flow cytometry (CD3-CD56+ and/or CD16+ cells) in 1,064 of 1,202 patients with follicular lymphoma treated with obinutuzumab or rituximab plus chemotherapy in the phase III GALLIUM trial (NCT01332968) and 1,287 of 1,418 patients with diffuse large B-cell lymphoma (DLBCL) treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP or R-CHOP) in the phase III GOYA trial (NCT01287741). The prognostic value of tumor NK-cell gene expression, as assessed by whole-transcriptome gene expression using TruSeq RNA sequencing, was also analyzed. The association of baseline variables, such as treatment arm, was evaluated using multivariate Cox regression models using a stepwise approach. RESULTS: In this exploratory analysis, low baseline peripheral blood NKCC was associated with shorter progression-free survival (PFS) in both follicular lymphoma [hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.02-2.14; P = 0.04] and DLBCL (HR, 1.36; 95% CI, 1.01-1.83; P = 0.04), and overall survival in follicular lymphoma (HR, 2.20; 95% CI, 1.26-3.86; P = 0.0058). Low tumor NK-cell gene expression was associated with shorter PFS in G-CHOP-treated patients with DLBCL (HR, 1.95; 95% CI, 1.22-3.15; P < 0.01). CONCLUSIONS: These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20-based immunochemotherapy.
650    _2
$a senioři $7 D000368
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    _2
$a buňky NK $x imunologie $x patologie $7 D007694
650    _2
$a folikulární lymfom $x krev $x farmakoterapie $x imunologie $x patologie $7 D008224
650    _2
$a difúzní velkobuněčný B-lymfom $x krev $x farmakoterapie $x imunologie $x patologie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a prognóza $7 D011379
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a míra přežití $7 D015996
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Oestergaard, Mikkel Z $u F. Hoffmann-La Roche Ltd, Basel, Switzerland. magda.klanova@lf1.cuni.cz mikkel.oestergaard@roche.com.
700    1_
$a Trněný, Marek $u Charles University General Hospital, Prague, Czech Republic.
700    1_
$a Hiddemann, Wolfgang $u University of Munich, Munich, Germany.
700    1_
$a Marcus, Robert $u Kings College Hospital, London, United Kingdom.
700    1_
$a Sehn, Laurie H $u Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada.
700    1_
$a Vitolo, Umberto $u A.O.U. Citta' Della Salute e della Scienza, S.C. Ematologia, Turin, Italy.
700    1_
$a Bazeos, Alexandra $u Imperial College London, London, United Kingdom.
700    1_
$a Goede, Valentin $u Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
700    1_
$a Zeuner, Harald $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Knapp, Andrea $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Sahin, Deniz $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Spielewoy, Nathalie $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Bolen, Christopher R $u Genentech, Inc., South San Francisco, California.
700    1_
$a Cardona, Andres $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Klein, Christian $u Roche Innovation Center Zurich, Schlieren, Switzerland.
700    1_
$a Venstrom, Jeffrey M $u Genentech, Inc., South San Francisco, California.
700    1_
$a Nielsen, Tina $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Fingerle-Rowson, Günter $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
773    0_
$w MED00001121 $t Clinical cancer research : an official journal of the American Association for Cancer Research $x 1078-0432 $g Roč. 25, č. 15 (2019), s. 4634-4643
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31053601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155359 $b ABA008
999    __
$a ok $b bmc $g 1599877 $s 1116418
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 15 $d 4634-4643 $e 20190503 $i 1078-0432 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace